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INTRODUCTION 
 
POLQ (DNA Polymerase Theta) is a member of the 
A family of DNA polymerases, which, unusually for 
this class of polymerases, synthesizes DNA with very 
low fidelity [1, 2]. The precise physiological functions 
of this protein are currently unclear. It has previously 
been suggested that mice deficient in POLQ had a 
substantially decreased frequency of mutations in 
immunoglobulin genes [3, 4]. However a recent study 
found that mutation types and frequencies were similar 
in wild type, POLQ-/-, POLH-/-, and POLQ-/- POLH-
/- mice [5]. Accordingly this group suggested that 
POLQ does not have a significant role in the 
hypermutation pathway. 
It has been suggested that POLQ has a role in base 
excision repair (BER) but this also remains unresolved. 
It has previously been shown in the DT40 chicken B 
cell lymphoma line, that POLQ/POLȕ mutants had 
significantly higher sensitivity to methyl 
methanesulfonate than either single mutant. Extracts 
obtained from this cell line were used to show that 
POLQ mutant cells have markedly reduced single 
nucleotide BER capacity in vitro and that this reduction 
was of a similar magnitude to cells deficient in POLȕ 
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ABSTRACT: 
Depletion of POLQ (DNA polymerase theta) has recently been shown to render 
tumour cells more sensitive to radiotherapy whilst having little or no effect on 
normal tissues. This finding led us to investigate whether tumours that overexpress 
POLQ are associated with an adverse outcome. We therefore correlated the clinical 
outcomes of two retrospective series of patients with early breast cancer with the 
expression levels of POLQ, as determined by microarray gene expression analysis. 
We found that a significant number of tumours overexpressed POLQ and that 
overexpression was correlated with ER negative disease (p=0.047) and high tumour 
grade (p=0.004), both of which are associated with poor clinical outcomes. POLQ 
overexpression was associated with poor relapse free survival rates on both 
univariate (HR 5.80; 95% CI, 2.220 to 15.159; p<0.001) and multivariate analysis 
(HR 8.086; 95% CI 2.340 to 27.948 p=0.001). Analysis of other published clinical 
series confirmed that POLQ overexpression is associated with adverse clinical 
outcomes. The poor prognosis associated with POLQ is independent of other clinical 
or pathological features.  The mechanism that causes this adverse outcome remains 
to be elucidated but may in part arise from resistance to adjuvant treatment. These 
findings, combined with the limited normal tissue expression of POLQ, make it a very 
appealing target for possible clinical exploitation. 
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[6]. These findings led to the suggestion that POLQ 
and POLȕ cooperate in BER. 
Recent biochemical analysis has shown that cloned 
full-length human POLQ as well as a C-terminal 
fragment of POLQ, have 5-deoxyribose phosphate (5-
dRP) lyase activity. The full-length protein and the C-
terminal fragment were shown to have BER activity in 
vitro [7]. Although these findings have been used to 
support the argument that POLQ may have a role in 
BER in vivo, it should be noted that the rate of 5-dRP 
lyase activity of POLQ is approximately 40 fold slower 
than that of POLȕ. Cells with deficiencies in the BER 
pathway have been shown to have increased sensitivity 
to temozolomide [8]. Since cells depleted of POLQ do 
not show hypersensitivity to this drug, it has been 
questioned as to whether POLQ has any 
physiologically significant role in BER [9].  
We have recently published a siRNA screen that 
aimed to identify molecular determinants of tumour 
radiosensitivity [9]. This study demonstrated that 
POLQ siRNA transfection resulted in radiosensitisation 
of a panel of tumour cell lines but had little or no effect 
on normal tissue lines. These differences reflect 
previous work showing significant disparity in 
expression between normal tissues and tumour cells 
[10]. Normal tissue expression appears to be mainly 
limited to lymphoid tissues such as the fetal liver, 
thymus, and bone marrow. However POLQ is known 
to be overexpressed in a large proportion of tumours 
derived from patients with colon, lung, and gastric 
cancer. 
In view of the in vitro evidence linking POLQ 
expression to tumour cell radioresistance, we 
hypothesised that POLQ overexpression may increase 
the likelihood of treatment failure in cancer patients, 
and therefore confer an adverse clinical prognosis.  
We therefore correlated the clinical outcomes of 
two series of breast cancer patients (n=279 in total) 
with the expression levels of POLQ as determined by 
microarray gene expression analysis. We also analysed 
the pathways associated with POLQ expression in vivo 
by data-mining gene expression data from published 
breast cancer studies (n=1015 samples). To the best of 
our knowledge this is the first study to demonstrate that 
POLQ is overexpressed in breast cancer, that its 
overexpression confers a significant adverse prognosis, 
and that it is associated with key cancer pathways. 
 
MATERIALS AND METHODS. 
 
Ethics Statement 
Informed consent was obtained and all clinical 
investigations were conducted according to the ethical 
standards and principles expressed in the Declaration 
of Helsinki. Ethical approval was obtained from the 
local research ethics committee. 
 
Patient Details  
 
Individual tumour samples were obtained from 
retrospective series of patients with early primary 
breast cancer who were treated in Oxford, UK, 
between 1989 and 1998. Patients received adjuvant 
chemotherapy and/or adjuvant hormone therapy, or no 
adjuvant treatment. Tamoxifen was used as endocrine 
therapy for 5 years in estrogen receptor (ER) positive 
patients. Patients who were t50 years of age, with 
lymph node positive tumors, or ER and/or a primary 
tumor >3 cm in diameter, received adjuvant 
cyclophosphamide, methotrexate, and 5-fluorouracil 
(CMF) for six cycles, in a three weekly intravenous 
regimen. Patients t50 years of age with ER, lymph 
nodepositive tumors also received CMF. Two series 
of 152 (Series 1) and 127 (Series 2) samples 
respectively were analysed. Series 1 has been described 
previously [11]; this series had completed 7 years of 
follow-up for all but 4 patients, and the median follow-
up time for patients leaving the study alive and without 
a relapse was 12 years. Series 2 is part of a published 
series [12]; the published cohort had 93 cases in 
common with Series 1, these have been excluded from 
this study so that Series 1 and 2 have no overlapping 
cases. Series 2 had completed 10 year of follow-up 
apart from one case. Patient demographic details of 
Series 1 and 2 as analysed in this study are summarised 
in supplementary table 1.  
 
RNA Extraction and Gene Expression Profiling 
 
Total RNA was isolated by Trizol method 
(Invitrogen, Carlsbad, CA) according to the 
manufacturers instructions. mRNA expression was 
measured using Affymetrix U133 arrays for Series 1 
and Illumina Human RefSeq-8 arrays (Illumina inc., 
San Diego, CA, USA) for Series 2. RNA was amplified 
using Ambion Illumina Amplification Kit. Methods for 
both protocols have been previously described [12, 13].  
Affymetrix data were pre-processed using gcrma [14]; 
signal from Illumina arrays was background subtracted 
with local background subtraction (BeadStudio). Data 
from both series were quantile normalized in 
Bioconductor (www.bioconductor.org) and logged 
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(base 2). The target sequence of the probes that 
corresponded to POLQ expression in Affymetrix and 
Illumina arrays are shown in supplementary table 2. 
Two additional published datasets of patients with 
early breast cancer were accessed to validate the 
findings observed in the Oxford datasets [15, 16]. 
 
Published Clinical Series 
 
NCBI Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) was searched for 
gene expression studies in cancer, published in peer-
reviewed journals, where microarrays were performed 
on frozen material extracted before treatment with 
either chemotherapy, radiotherapy or endocrine 
treatment. Five data sets [11, 15, 17] of 1015 samples 
in total (supplementary table 3) were selected that used 
latest generation Affymetrix 3 array platforms 
(Affymetrix U133 and plus2, www.affymetrix.com). 
All handling and processing of the downloaded data 
was performed as previously described [18]. 
 
Data-mining of Gene Expression Data 
 
Seed-clustering with bootstrap resampling was 
applied as previously described [18] to obtain genes 
co- and inversely expressed with POLQ in the 1015 
published breast cancer samples. In short, the two 
probesets targeting POLQ (supplementary table 2) 
were chosen as initial seeds. Transcripts on the arrays 
showing significant association (Spearman Rank Test, 
Bonferroni multiple test correction) with each seed 
after bootstrap resampling of the breast cancer samples 
were considered. Amongst these, transcripts showing a 
concordant association with both seeds that was 
significantly higher than observed by random 
simulation were selected as POLQ co-/inversely 
expressed genes. A pathway enrichment analysis was 
thus performed using GeneCodis2 [19] to study the 
Gene Ontology classes and the KEGG pathways which 
are over-represented in POLQ co-/inversely expressed 
genes. 
 
Survival Analysis 
 
Endpoints were relapse free survival for Series 1; 
and distant-relapse free survival and recurrence free 
survival as defined by the STEEP criteria [20] for 
Series 2. Endpoints as published were considered for 
the other datasets. Univariate and multivariate analysis 
was performed. Cox multivariate models were reduced 
using stepwise backward likelihood selection. In 
univariate analyses, expression of POLQ and other 
genes was considered either as binary variable, with 
median expression as binary cut-off, or as continuous 
variable, ranked and normalised between 0 and 1. In 
multivariate analysis the latter was always considered. 
  
RESULTS 
 
POLQ is overexpressed in breast cancer compared 
to normal breast tissue 
 
 In order to assess POLQ expression, we identified 
two independent gene expression datasets that were 
obtained using arrays from different manufacturers. 
Series 1 and 2 were obtained using Affymetrix and 
Fig 1: POLQ Expression in Breast Cancer 
A) Breast cancer samples, Series 1, described in this study (N=152). No normal breast tissue samples were
available for Series 1 so POLQ data were normalised to the sample with the lowest expression of POLQ (named T0).
Expression fold change (FC) between all other tumours and T0 is shown for POLQ (207746_at). Expression is
measured by Affymetrix array and quantile normalized.  
B) Breast cancer samples, Series 2, (N=127) described in this study. The FC between POLQ (ILMN_1450687)
expression in each tumour and the median expression of 10 normal pools is shown. Expression is measured by
Illumina arrays and quantile normalized. 
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Illumina arrays respectively. POLQ expression was 
normalised to the lowest level of tumour expression in 
the Affymetrix series, and to a panel of normal breast 
tissue samples for the Illumina series. POLQ 
expression is upregulated in a large proportion of 
breast tumour samples (Fig 1).  
 
POLQ overexpression is independently associated with 
significantly worse relapse free survival (RFS) rates 
 
The samples from Series 1 were divided into the 
top and bottom 50th centiles and a univariate analysis 
Fig. 2: POLQ expression is prognostic in breast cancer independently from clinico-pathological variables.
A) Univariate analysis in 152 breast cancers (Series 1). POLQ expression is divided in two groups by median
value. 
B) POLQ expression is associated with tumour grade (left) and ER status (right) in Series 1 and 2 described in
this study (Affymetrix and Illumina arrays respectively) and two published series (Affymetrix arrays, see
Methods), although grade information was not available for GSE2034. Boxes summarize the median, quartiles
and extreme values of POLQ expression in the different categories. One outlier is shown (circle), defined as
case with values between 1.5-3 box lengths from the edge of the box.  Mann-Whitney and Spearman Rank
Association significance levels for the null hypotheses of POLQ expression not varying with ER and Grade
respectively, are indicated on the highest category of each plot:*=p<0.05, **=p<0.01, ***=p<0.001. 
C) Forest plot of POLQ Hazard Ratio for Survival Endpoints in univariate and multivariate analysis in the 2
series described in this study and 2 published datasets (GEO Ids shown). Dots represent Hazard Ratios of
POLQ expression and grey bars the 95% confidence intervals. Dot dimensions are proportional to dataset size.
The expression of POLQ is entered in this model as a continuous ranked variable, normalised between 0
(lowest rank) and 1 (highest rank). RFS= Recurrence Free Survival, DRFS=Distant Relapse Free Survival,
DSS= Disease Specific Survival. 
A
B
C
Hazard Ratio for Survival Endpoint
Univariate
Series 1 [RFS]
Series 2 [DRFS]
GSE3494 [DSS]
GSE2034 [RFS]
Multivariate
Series 1 [RFS]
Series 2 [DRFS]
GSE3494 [DSS]
GSE2034 [RFS]
1 50.1 0.5
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Fig. 3: Pathway analysis and overlap with
prognostic signatures of POLQ co-expressed
genes.  
Seed-clustering was used in 1015 breast cancer
samples to identify genes whose expression was co-
and inversely associated with POLQ expression. 
A) Over-represented KEGG pathways and B) GO
Biological processes amongst genes co-expressed
with POLQ. The number of genes in each pathway is
shown in blue, top x-axis, and a hypergeometric test
p-value (FDR adjustment for multiple testing) is
shown in red, bottom axis. 
C) Venn-diagram showing the overlap of genes
whose expression is co- (POLQ_Corr) and inversely
(POLQ_Inv) associated with expression of POLQ with
the Genomic Grade Index Signature (GGI) [25], the
76-gene signature (Sign76gene) [16], and the 70-
genes signature (Sign70genes) [24]. 
of the differences in RFS was conducted (Fig 2A). 
POLQ overexpression was associated with a markedly 
increased risk of disease relapse (HR 5.80; 95% CI, 
2.220 to 15.159; p<0.001). We then correlated the 
level of POLQ expression with multiple pathological 
and demographic features such as patient age, tumour 
grade and tumour size. We found that POLQ 
overexpression correlated with both ER negative 
disease (p=0.047) and high tumour grade (p=0.004) 
(Fig 2B). As both of these features are recognised as 
being associated with poor clinical outcomes [21-23], 
we performed a multivariate analysis which showed 
that POLQ expression confers a poor prognosis which 
is independent of any other clinical features (HR 
8.086; 95% CI 2.340 to 27.948; p=0.001). The 
multivariate models contained POLQ as continuous 
variable, ranked and normalised between 0 and 1, and 
the following clinical features; ER status, lymph node 
status, patient age, tumour grade, tumour size. To 
confirm the validity of this finding we performed 
further univariate and multivariate analyses on Series 2 
and the two additional datasets previously described 
(supplementary table 4). In total, three of the four 
datasets analysed demonstrated that POLQ 
overexpression was strongly associated with 
significantly worse survival outcomes (Fig 2C).  
 
Clustering analysis identifies genes co-expressed 
with POLQ with functions in key cancer pathways 
 
 In order to identify genes which were co-expressed 
with POLQ, a seed-clustering analysis was performed 
on gene expression data obtained from five different 
breast cancer data sets (details of datasets in 
supplementary table 3). This identified a total of 97 
genes that were strongly associated with POLQ 
overexpression in breast cancer (supplementary table 
5). Pathway analysis of these genes showed that genes 
co-expressed with POLQ are involved in several 
pathways that have been associated with cancer 
development and progression such as cell cycle 
progression, p53 signalling, Wnt signalling and DNA 
replication (Fig 3A and 3B).  
 
Genes co-expressed with POLQ overlap with 
several genes that comprise the Gene expression 
Grade Index (GGI) 
 
Previous studies such as the 70-gene expression 
signature [24] have identified groups of genes that 
form expression profiles which correlate with clinical 
outcome. Although POLQ expression has not 
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previously been shown to be independently associated 
with clinical outcome, it is interesting to note that 
POLQ is included in both the GGI [25], and the 76-
gene signature [16]. The correlation between POLQ 
expression and tumour grade and prognosis (Fig. 2) led 
us to assess whether genes that are co-expressed with 
POLQ are included in these validated gene expression 
signatures (Fig. 3C). Eighteen of the genes that are 
significantly co-expressed with POLQ (supplementary 
table 5) are components of the GGI index (Table 1). 
The large number of genes that overlap between these 
two groups may account for the clinical correlation 
between POLQ expression and high tumour grade. 
 
POLQ overexpression confers a poor prognosis that 
is independent of published prognostic signatures 
 
As POLQ has several genes in common with the 
GGI signature, and is itself part of the GGI and 76 
gene signatures, we assessed whether POLQ 
expression remained an independent predictor of 
relapse when these signatures were included in a 
multivariate analysis of the data from Series 1 (Fig 4A 
and supplementary table 6). POLQ expression 
remained a strong, independent predictor of disease 
relapse after statistical consideration of these validated 
expression profiles and reinforces the close association 
between POLQ expression and adverse outcome.   
 
The poor prognosis associated with POLQ 
expression is independent of Cyclin E expression 
 
 CCNE2 (cyclin E) is the only gene that is a 
component of all three expression signatures and which 
is also co-expressed with POLQ. As cyclin E 
overexpression has been identified as being 
independently associated with an adverse outcome in 
breast cancer patients [26], we considered whether the 
adverse prognosis associated with POLQ expression 
may simply be due to the observation that CCNE2 is 
often co-expressed with POLQ. We therefore 
performed a multivariate analysis of the data from 
Series 1 that included CCNE2 expression and found 
that POLQ and CCNE2 were both independently 
associated with an increase in RFS (Fig 4A). It is 
notable that tumours that overexpress both POLQ and 
CCNE2 confer an extremely poor prognosis relative to 
the other groups (HR 3.26; 95% CI 1.88 to 5.66; 
p<0.001) (Fig 4B). Tumours that do not overexpress 
either gene are associated with a good prognosis, and 
those that overexpress only one of the genes are 
associated with an intermediate prognosis. This data 
suggests that the biological mechanisms by which 
POLQ and CCNE2 confer a poor prognosis might be 
independent of each other. These results could not be 
confirmed in the other datasets considered, where 
POLQ lost significance after inclusion of CCNE2. 
However it should be noted that Series 1 is the only 
one in which patients did not receive systemic 
chemotherapy which is a potential confounding factor 
for prognostic analysis. 
 
DISCUSSION  
 
We have recently demonstrated that tumour cells 
depleted of POLQ are rendered more sensitive to 
radiotherapy and that its limited expression in normal 
tissues made POLQ a potentially exploitable clinical 
target [9]. In this study we have demonstrated that 
Table 1:  
Overlap between the Genomic Grade Index (GGI) signature 
[25] and transcripts co- or inversely associated with POLQ in 
seed-clustering of 1015 breast cancer samples 
Symbol 
GGI 
grades 
Accession 
Number 
Gene 
ID 
Full name/description 
Transcripts co-expressed with POLQ 
AURKA G3 NM_003158 6790 aurora kinase A 
CCNB2 G3 NM_004701 9133 cyclin B2 
CCNE2 G3 NM_004702 9134 cyclin E2 
CDKN3 G3 AF213033 1033 
cyclin-dependent kinase 
inhibitor 3 (CDK2-
associated dual specificity 
phosphatase) 
CEP55 G3 NM_018131 55165 centrosomal protein 55kDa 
ESPL1 G3 NM_012291 9700 
extra spindle pole bodies 
homolog 1 (S. cerevisiae) 
ESPL1 G3 D79987 9700 
extra spindle pole bodies 
homolog 1 (S. cerevisiae) 
GTSE1 G3 NM_016426 51512 
G-2 and S-phase expressed 
1 
KIFC1 G3 BC000712 3833 kinesin family member C1 
LMNB1 G3 NM_005573 4001 lamin B1 
MCM2 G3 NM_004526 4171 
MCM2 minichromosome 
maintenance deficient 2, 
mitotin (S. cerevisiae) 
MELK G3 NM_014791 9833 
maternal embryonic 
leucine zipper kinase 
MYBL2 G3 NM_002466 4605 
v-myb myeloblastosis viral 
oncogene homolog 
(avian)-like 2 
NA G3 BE966236 NA NA 
NCAPG G3 NM_022346 64151 
non-SMC condensin I 
complex, subunit G 
POLQ G3 NM_006596 10721 
polymerase (DNA 
directed), theta 
PRC1 G3 NM_003981 9055 
protein regulator of 
cytokinesis 1 
RRM2 G3 BC001886 6241 
ribonucleotide reductase 
M2 polypeptide 
TIMELESS G3 NM_003920 8914 
timeless homolog 
(Drosophila) 
TRIP13 G3 NM_004237 9319 
thyroid hormone receptor 
interactor 13 
Transcripts whose expression is inversely associated  with POLQ 
expression 
CX3CR G1 U20350 1524 
chemokine (C-X3-C motif) 
receptor 1 
s G1 and G3 are the sets of
 genes with increased expression in histologic 
grade 1 and 3 tumors, respectively. 
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POLQ is frequently upregulated in breast cancers. 
Although POLQ overexpression has previously been 
demonstrated in lung, gastric and colorectal cancers 
[10], to the best of our knowledge, this has not 
previously been shown in breast cancer. 
In this current study we have demonstrated strong 
associations between POLQ expression and the 
presence of other individual factors such as tumour 
grade and ER negative disease that are known to confer 
an adverse prognosis.  We have also demonstrated that 
POLQ overexpression is associated with markedly 
increased rates of disease relapse, and using 
multivariate analysis, that these increased failure rates 
are independent of its association with features like 
tumour grade and ER status. 
The mechanisms by which POLQ overexpression 
causes these adverse outcomes are not presently clear. 
POLQ associated radioresistance is likely to contribute 
to these findings and further work is required to assess 
whether POLQ expression increases the tumour cell 
resistance to the cytotoxic and endocrine treatments 
typically used to treat breast cancers. The co-
expression of POLQ with genes linked to pathways 
associated with tumour progression, as well as several 
genes that are contained within the gene expression 
grade index, suggests that POLQ overexpression 
promotes a more aggressive phenotype, increasing the 
likelihood of disease recurrence. 
The clinical significance of tumour expression of 
POLQ has not previously been examined in detail. A 
previous study in colorectal cancer correlated the 
expression levels of genes involved in DNA replication 
with clinical outcomes in 74 patients with colorectal 
cancer [27]. Although POLQ was not independently 
associated with adverse outcome, its co-overexpression 
with at least three other genes involved in DNA 
replication firing (from among CDC45, CDC6, 
CDT1, SLD5, MCM2, and MCM7) was associated 
with a worse overall survival. The overall significance 
of POLQ on this finding is not clear since MCM7 
overexpression was shown to independently be 
associated with adverse survival rates. This group 
suggested that the expression of these genes could 
produce a more aggressive tumour phenotype by 
contributing to replication stress. As POLQ is known 
to repair DNA damage in an error-prone fashion [1, 2], 
it would seem likely that the poor prognosis that we 
have described in this study is partially due to POLQ 
contributing to increased replication stress and 
genomic instability. 
To the best of our knowledge this is the first study 
to demonstrate an adverse association with POLQ 
Fig. 4: POLQ expression shows prognostic potential in multivariate models including clinical
variables, published signatures and CCNE2.  
A) Forest plot of POLQ Hazard Ratio for Recurrence Free Survival in multivariate analysis of Series 1. Dots
represent Hazard Ratios (dimensions are proportional to dataset size) and grey bars the 95% confidence
intervals. In each analysis, a multivariate model including POLQ expression, all significant clinical variables,
CCNE2 expression, and published signature scores (GGI, 76-gene or 70-gene signature) is derived. The
expression of POLQ, signature scores and CCNE2 are entered in these models as continuous ranked variables,
normalised between 0 (lowest rank) and 1 (highest rank). See methods for more details. 
B) Kaplan-Meier plots of Series 1 data. POLQ and CCNE2 expression divided by median value (- indicates below
median, + above median). A Helmert contrasts analysis demonstrated that tumours overexpressing both POLQ
and CCNE2 were associated with worse outcomes than the average of the other groups (HR 3.26; 95% CI 1.88 to
5.66; p<0.001) 
A B
Recurrence Free Survival
CCNE2 Model
GGI Model
76gene Model
70gene Model
1 50.1 0.5
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expression in patients with breast cancer. In recent 
years, attempts have been made to identify gene 
expression signatures that are capable of predicting 
patient outcomes with greater accuracy than is 
currently achievable in routine clinical practice. It is 
possible that specific gene expression profiles could 
identify the likelihood of response to individual 
therapies, enabling clinicians to refine the adjuvant 
therapy offered to individual patients. The GGI 
signature [25] identified 97 genes with differential 
expression between low and high grade breast 
carcinomas. This signature enabled a more accurate 
and refined assessment of the risk of disease recurrence 
in patients with intermediate grade disease. Subsequent 
studies have confirmed the ability of the GGI signature 
to accurately predict disease relapse [13, 28]. A 
separate expression profile has been created to more 
accurately identify patients at risk of developing 
metastatic disease [16]. This study used tumours 
derived from patients who did not receive adjuvant 
systemic therapy, thereby eliminating potentially 
confounding predictive factors occurring as a result of 
systemic treatment. The resulting 76 gene signature 
was shown to predict both distant failure as well as 
overall survival. Further studies have reinforced the 
prognostic accuracy of this gene signature [29, 30]. A 
third gene expression profile utilising a 70 gene 
signature has also been shown to predict clinical 
outcome [24] and has also been subsequently validated 
[31]. The prognostic effect of POLQ expression on its 
own has not previously been assessed, but it is 
interesting to note that POLQ is a component of both 
the GGI and the 76 gene expression profiles. Given 
the large differences that we have shown in relapse 
rates on the basis of POLQ expression, and that these 
differences are maintained on multivariate analyses 
that include these signatures, it is possible that POLQ 
may be amongst the most important determinants 
within these signatures.  
Pathway analysis identified several genes, 
including Cyclin E, that were frequently co-expressed 
with POLQ. Cyclin E over expression has been 
identified as being associated with an adverse outcome 
in breast cancer patients [26]. It is the only gene that is 
a component of all three gene expression signatures 
and which is also frequently co-expressed with POLQ. 
Cyclin E binds to cyclin-dependent kinase-2 (cdk-2), 
permitting the transition from G1 to S-phase [32]. 
Increased cyclin E induces enhanced cdk-2 activity, 
accelerating G1/S transition [33]. There is substantial 
evidence to suggest that CCNE overexpression confers 
a poor prognosis in breast cancer. A recent meta-
analysis of 12 independent studies involving 2,534 
patients, demonstrated that the combined HR estimate 
for overall survival and breast cancer specific survival 
was 2.98 (95% CI, 1.854.78) and 2.86 (95% CI, 1.85
4.41) in univariate and multivariate analysis, 
respectively [34]. Although there is ongoing debate as 
to which fragments of cyclin E are important in 
predicting outcome [35], the evidence supporting its 
use in routine clinical assessment have led for calls for 
large scale clinical trials [34]. In this study we have 
again confirmed that cyclin E overexpression was 
associated with a poor clinical prognosis on 
multivariate analysis. In addition we have shown that 
tumours expressing both POLQ and CCNE2 are 
associated with an extremely poor outcome. This 
suggests that these genes confer a poor prognosis 
through separate mechanisms. Larger studies are 
required to investigate whether the risk of relapse from 
tumours overexpressing cyclin E could be better 
assessed if further stratified by POLQ expression 
levels. 
Independently of its association with other known 
poor pathological features, POLQ overexpression is 
associated with increased relapse rates. This is the first 
study to demonstrate that POLQ overexpression is 
associated with an extremely poor outcome in breast 
cancer on both univariate and multivariate analysis. 
We believe that the poor prognosis associated with 
POLQ expression, the known radiosensitivity induced 
by its depletion, and its highly limited normal tissue 
expression makes POLQ an extremely appealing target 
for clinical exploitation. 
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